Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada.

Jennifer Fenna, Daniel McCormack, Sophie Kitchen, Diana Martins, Tara Gomes, Mina Tadrous

Open access · bronzeAbstract read

In one paragraph

Article in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 51% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jennifer FennaLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services, Alberta Health Services, Edmonton, Alberta, Canada.

Daniel McCormackICES, Toronto, Canada.

Sophie KitchenLi Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada.

Diana MartinsLi Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada.

Tara GomesLeslie Dan Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute, Unity Health Toronto; and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.

Mina TadrousLeslie Dan Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada.

University of Toronto · CAUnity Health TorontoInstitute for Clinical Evaluative Sciences · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntirheumatic AgentsArthritis, RheumatoidBiosimilar PharmaceuticalsCross-Sectional StudiesEtanerceptFemaleHumansInflammatory Bowel DiseasesInfliximabMaleMiddle AgedOntarioPharmaceutical ServicesAntirheumatic AgentsBiosimilar PharmaceuticalsEtanerceptInfliximab

Identifiers

PMID33769851

PMCPMC10391289

OpenAlexW3137020909

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.